31. January 2020

Zedira supports Gordon Research Conference



“Known and Emerging Transglutaminase-Related Diseases and New Methods for Detection and Treatment”

Zedira is very proud to support for the 6th time the Gordon Research Conference dedicated to Transglutaminase. The conference will be held from June 14th until June 19th, 2020 at Mount Snow in West Dover, VT, USA.

“This meeting will allow opportunity for discussion of recent results relating the activities of all transglutaminase enzymes with cardiovascular diseases, neurological diseases, cancer and signalling disorders, celiac disease and inflammation, fibrosis and remodelling disorders. Additionally, this meeting will focus on emerging diseases associated with this class of enzymes, and new methods for their investigation.” (Source GRC)



Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
    Read more All news
  • Zedira supports Gordon Research Conference
    Read more All news
  • imagePress release: Zedira announces ISO 9001:2015 certification
    Read more All news
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
    Read more All news
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
    Read more All news
  • imagePreview: Catalogue Editorial 2019
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

    All events
  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

    All events